论文部分内容阅读
目的:观察生脉注射液联合常规西药治疗慢性阻塞性肺疾病(COPD)缓解期患者的临床疗效及其对患者呼吸、肺和免疫功能的改善作用。方法:选取94例COPD缓解期患者为研究对象,随机分为对照组和观察组各47例。对照组给予抗炎、抗感染、止咳化痰、解痉、氧疗等常规治疗,观察组在常规治疗基础上联合生脉注射液治疗。观察2组临床疗效,比较2组临床症状(包括咳喘、心悸、发绀及肺部湿啰音等)的消失时间和住院时间以及治疗前后肺功能指标[用力肺活量(FVC)、1秒用力呼气量(FEV1)、1秒率(FEV1%)]和免疫球蛋白指标[免疫球蛋白G(lgG)、免疫球蛋白A(lgA)、免疫球蛋白M(lgM)]的变化情况。结果:治疗总有效率观察组为95.74%,高于对照组的80.85%,2组比较,差异有统计学意义(P<0.05)。治疗后观察组咳喘、心悸、发绀、肺部湿啰音等的消失时间以及住院时间均短于对照组(P<0.05)。治疗前,2组FVC、FEV1、FEV1%以及lgG、lgA、lgM水平比较,差异均无统计学意义(P>0.05)。治疗后,观察组的FVC、FEV1、FEV1%以及lgG、lgA、lgM水平均高于对照组与同组治疗前(P<0.05)。结论:生脉注射液联合常规西药治疗COPD缓解期患者临床疗效显著,能有效改善患者的症状和肺功能,提高患者的免疫力。
Objective: To observe the clinical efficacy of Shengmai injection combined with conventional western medicine in the treatment of patients with chronic obstructive pulmonary disease (COPD) in remission and its effect on improving respiratory, pulmonary and immune function in patients. Methods: A total of 94 patients with COPD during remission were selected as study subjects and randomly divided into control group and observation group (n = 47). Control group were given anti-inflammatory, anti-infection, cough and phlegm, spasm, oxygen therapy and other conventional treatment, the observation group on the basis of conventional therapy combined Shengmai injection. The clinical curative effect was observed in two groups. The disappearance time and hospital stay of two groups of clinical symptoms (including cough, palpitation, cyanosis and pulmonary araucation) were compared. The pulmonary function indexes (FVC, (FEV1), 1 second rate (FEV1%)] and the changes of immunoglobulin indicators [IgG, IgA, IgM]. Results: The total effective rate in observation group was 95.74%, which was higher than that in control group (80.85%). There was significant difference between two groups (P <0.05). After treatment, the disappearance time of cough, heart palpitations, cyanosis, lung wet rales, and hospital stay in the observation group were shorter than those in the control group (P <0.05). Before treatment, there was no significant difference in FVC, FEV1, FEV1% and lgG, lgA, lgM between the two groups (P> 0.05). After treatment, FVC, FEV1, FEV1% and lgG, lgA, lgM levels in the observation group were significantly higher than those in the control group and the same group before treatment (P <0.05). Conclusion: Shengmai injection combined with conventional western medicine in the treatment of patients with COPD significantly clinical efficacy, can effectively improve the patient’s symptoms and lung function, improve patient immunity.